Suppr超能文献

血清淀粉样蛋白 A 水平与儿童 COVID-19 严重程度的关系。

Serum Amyloid A Levels and Severity of COVID-19 in Children.

机构信息

Department of Pediatric Infectious Diseases, University of Health Sciences, Tepecik Training and Research Hospital, Izmir, Turkey. Correspondence to: Dr Selin Tasar, Department of Pediatric Infectious Diseases, University of Health Sciences, Tepecik Training and Research Hospital, Izmir, Turkey.

Department of Pediatric Infectious Diseases, University of Health Sciences, Tepecik Training and Research Hospital, Izmir, Turkey.

出版信息

Indian Pediatr. 2023 Mar 15;60(3):217-220. doi: 10.1007/s13312-023-2838-1.

Abstract

OBJECTIVE

The aim of this study was to determine the availability of serum amyloid A (SAA) in the diagnosis of coronavirus disease 2019 (COVID-19), to asses disease severity and to predict hospitalization status.

METHODS

Between March, 2020 and March, 2021, a total of 80 children (40 cases with COVID-19 and 40 cases in healthy group) were included in this study. Patients were divided into two groups (mild and moderate/severe) to evaluate SAA levels in terms of clinical severity and also hospitalization status.

RESULTS

Comparisons between the two groups revealed that median SAA values were significantly higher in children with COVID-19 than in their healthy peers (21.45vs3.05 mg/L, P=0.002). There was no significant difference in the median serum SAA levels between mild and moderate/severe clinical disease (P=0.837). The SAA difference between the two groups with regards to hospitalization was not statistically significant (P=0.098).

CONCLUSIONS

Although SAA level was found to be higher in children with COVID 19 compared to healthy controls, the sensitivity of SAA for the disease was found to be low. In addition, there was no difference between the groups in terms of clinical severity.

摘要

目的

本研究旨在确定血清淀粉样蛋白 A(SAA)在 2019 冠状病毒病(COVID-19)诊断中的可用性,评估疾病严重程度并预测住院状态。

方法

本研究共纳入 80 例儿童(40 例 COVID-19 患儿和 40 例健康对照组),时间为 2020 年 3 月至 2021 年 3 月。根据临床严重程度将患者分为两组(轻症和中/重症),并评估 SAA 水平与住院状态的关系。

结果

两组比较显示,COVID-19 患儿的 SAA 中位数显著高于健康对照组(21.45vs3.05mg/L,P=0.002)。轻症和中/重症患儿的血清 SAA 水平中位数无显著差异(P=0.837)。两组间关于住院的 SAA 差异无统计学意义(P=0.098)。

结论

尽管 COVID-19 患儿的 SAA 水平高于健康对照组,但 SAA 对疾病的敏感性较低。此外,两组在临床严重程度方面无差异。

相似文献

1
Serum Amyloid A Levels and Severity of COVID-19 in Children.
Indian Pediatr. 2023 Mar 15;60(3):217-220. doi: 10.1007/s13312-023-2838-1.
3
Expressions of SAA, CRP, and FERR in different severities of COVID-19.
Eur Rev Med Pharmacol Sci. 2020 Nov;24(21):11386-11394. doi: 10.26355/eurrev_202011_23631.
5
Serum Amyloid A Protein as a useful biomarker to predict COVID-19 patients severity and prognosis.
Int Immunopharmacol. 2021 Jun;95:107512. doi: 10.1016/j.intimp.2021.107512. Epub 2021 Mar 2.
6
The value of serum amyloid A for predicting the severity and recovery of COVID-19.
Exp Ther Med. 2020 Oct;20(4):3571-3577. doi: 10.3892/etm.2020.9114. Epub 2020 Aug 7.
7
Role of Serum Amyloid A as a Biomarker for Predicting the Severity and Prognosis of COVID-19.
J Immunol Res. 2022 Nov 24;2022:6336556. doi: 10.1155/2022/6336556. eCollection 2022.
10
Serum amyloid A as a biomarker in differentiating attacks of familial Mediterranean fever from acute febrile infections.
Clin Rheumatol. 2020 Jan;39(1):249-253. doi: 10.1007/s10067-019-04765-1. Epub 2019 Sep 4.

引用本文的文献

2
Research Trends in Proteomic Studies Using Serum from COVID-19 Patients: A Bibliometric Analysis.
Curr Med Chem. 2025;32(12):2275-2290. doi: 10.2174/0109298673286915240329063441.

本文引用的文献

2
Prospective selected biomarkers in COVID-19 diagnosis and treatment.
Biomark Med. 2021 Oct;15(15):1435-1449. doi: 10.2217/bmm-2021-0038. Epub 2021 Sep 20.
6
The dynamics of inflammatory markers in coronavirus disease-2019 (COVID-19) patients: A systematic review and meta-analysis.
Clin Epidemiol Glob Health. 2021 Jul-Sep;11:100727. doi: 10.1016/j.cegh.2021.100727. Epub 2021 Mar 20.
7
Expressions of SAA, CRP, and FERR in different severities of COVID-19.
Eur Rev Med Pharmacol Sci. 2020 Nov;24(21):11386-11394. doi: 10.26355/eurrev_202011_23631.
8
Associations between serum amyloid A, interleukin-6, and COVID-19: A cross-sectional study.
J Clin Lab Anal. 2020 Oct;34(10):e23527. doi: 10.1002/jcla.23527. Epub 2020 Aug 28.
9
The value of serum amyloid A for predicting the severity and recovery of COVID-19.
Exp Ther Med. 2020 Oct;20(4):3571-3577. doi: 10.3892/etm.2020.9114. Epub 2020 Aug 7.
10
Predicting Disease Severity and Outcome in COVID-19 Patients: A Review of Multiple Biomarkers.
Arch Pathol Lab Med. 2020 Dec 1;144(12):1465-1474. doi: 10.5858/arpa.2020-0471-SA.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验